LifeStance turns profitable and leans into specialty — the tape is listening

A 95% three-month re-rating as Q2 beats on every line, net income goes positive, and a psychedelics option enters the story

LFST · Earnings Call · 2026-08-06

The operating engine is compounding

Across the board, LifeStance delivered a quarter management didn't hesitate to call "exceptional," and the tape agreed — shares are up ~95% in the past 90 trading days, a violent reversal from a drawdown that had cut them 57% below the 2021 IPO peak. Revenue grew 26% to $435M, Adjusted EBITDA hit 15.2% of revenue (up more than 500 basis points year-over-year), and the company printed its first meaningful positive net income. This is a name in motion, not a dead-cat bounce. The beat came from both halves of the equation: visit volumes up 19% and total revenue per visit (TRPV) up 6% to $167. CFO Ryan McGroarty pointed to unusually strong visibility on the rate side: “we have good line of sight into the rate increases for the full year... we updated our guidance from low to mid-single digits to mid-single digits.” — Ryan McGroarty, Chief Financial Officer · 2026-08-06 That is a real upgrade — just one quarter ago the company was still absorbing the last of a one-off "unique payer dynamic" and guiding TRPV roughly flattish. The revenue per visit acceleration, combined with record clinician productivity (visits per average clinician +7% for a third straight quarter), is what's driving the Center Margin to 35.2%. The fundamentals corroborate the narrative. Total revenue has compounded at roughly 19% annually for five years to a ~$1.7B run-rate, and net income swung from a $7M loss a year ago to +$14M in Q1 and +$24M in Q2, an improvement of $27 million year-over-year. Operating margin has crossed positive for the first time in the company's public history, at 5.5% in Q1.

We also finished with positive net income of $24 million in the quarter, which was an improvement of $27 million from the second quarter of last year.
Ryan McGroarty, Chief Financial Officer · 2026-08-06

Specialty services become the growth engine

The freshest signal this quarter is specialty services — TMS and Spravato for treatment-resistant depression — which CEO David Bourdon framed as a launchpad for something even bigger:

we're monitoring that and we think that is a great opportunity for us and we're set up really well if that were to be approved by the FDA... leveraging our center footprint as well as even some of the foundational work we've done to roll out Spravato.
David Bourdon, Chief Executive Officer · 2026-08-06

That is a direct nod to Eli Lilly's recent acquisition in psychedelics — a catalyst that wasn't on the radar one quarter ago. LifeStance's 575+ centers, hybrid model and payer contracts give it an essentially capital-light option on psychedelics. Specialty services were roughly $50M of revenue last year, growing about 40% this year, and management expects them to outgrow the core business for years to come. The specialty push pairs with a second new theme: outcomes-based differentiation. LifeStance published its second outcomes white paper covering nearly 140,000 LifeStance patients, finding at least 75% showed clinically meaningful improvement regardless of generation or region. Bourdon framed this as an industry inflection: “The majority of payers are still focused on access... And then there are a few leading payers that are starting to shift towards quality and outcomes. And we welcome that change.” — David Bourdon, Chief Executive Officer · 2026-08-06

Capital returns and disciplined expansion

The balance sheet now gives LifeStance real optionality. Free cash flow was $88M in Q2 — though roughly $60M of that reflects favorable payroll and 401(k) timing that will reverse in Q3 — and net leverage sits at just 0.2x. After deploying $97M of its first $100M buyback, the Board authorized another $100M. Management is also restarting the M&A engine, but deliberately, via small tuck-ins into new geography — only about half of the 150 largest U.S. markets are penetrated. This is a marked contrast to the pre-IPO era of large, onerous deals: “at the same time, as we are going down market, those opportunities seem to have more appropriate valuations” — David Bourdon, Chief Executive Officer · 2026-02-25 — a discipline that's now showing up in margin expansion. The payer-contract cleanup begun two years ago is complete: “We are pretty much complete on the journey of cleaning up the payer contracts.” — David Bourdon, Chief Executive Officer · 2026-02-25 That, plus AI use cases in the revenue cycle and new-patient scheduling, is what's driving operating leverage. Management's long-term margin target remains 15-20% Adjusted EBITDA — "20% not being a ceiling" — and Q2's 15.2% shows the path, as Ryan put it: “long-term margins in the 15% to 20% range with 20% not being a ceiling” — Ryan McGroarty, Chief Financial Officer · 2026-08-06. Three things changed this quarter — a durable profitability crossover, a credible specialty engine with a psychedelics option, and systematic capital returns — and together they explain the re-rating. At just 1.7x forward revenue, the market is pricing LifeStance as a fixer-upper, not a compounding growth asset. That gap is the opportunity.